Daily Sepsis Research Analysis
Analyzed 67 papers and selected 3 impactful papers.
Summary
Three studies advanced sepsis science across mechanism, systems biology, and translational strategy: an anti-virulence approach targeting MRSA PSMα3–STAT1 signaling reduced infection in murine sepsis; a metabolic–epigenetic checkpoint (histone H3K18 lactylation) was shown to control autophagy genes and reverse immunosuppression; and time-resolved multi-omics mapped coordinated shifts in gut cells, microbiome, metabolites, and proteins during pneumonia-induced sepsis.
Research Themes
- Anti-virulence strategies targeting host–pathogen signaling in MRSA sepsis
- Metabolic–epigenetic control of autophagy and immunosuppression in sepsis
- Time-resolved multi-omics of gut ecosystem remodeling during sepsis
Selected Articles
1. Targeting phenol-soluble modulin α3-driven M1 macrophage polarization and necroptosis mitigates MRSA infection in mice.
This mechanistic study shows that MRSA virulence factor PSMα3 drives M1 macrophage polarization and necroptosis via an ISGF3–necrosome axis downstream of FPR2. Pharmacologic inhibition of STAT1 with the approved drug fludarabine attenuated MRSA infection in murine sepsis and pneumonia models, positioning anti-virulence targeting as a translational strategy.
Impact: Reveals a targetable host–pathogen signaling mechanism and demonstrates efficacy of a repurposed, clinically approved drug in relevant murine sepsis models.
Clinical Implications: Suggests a potential adjunctive, anti-virulence therapy for MRSA sepsis by inhibiting STAT1 signaling; supports future dose-finding and safety trials combining fludarabine with antibiotics.
Key Findings
- PSMα3 promoted M1 macrophage polarization and necroptosis linked via ISGF3–necrosome interactions.
- Formyl peptide receptor 2 (FPR2) functioned as the key receptor for PSMα3-mediated effects.
- STAT1 inhibition with fludarabine mitigated MRSA infection in murine sepsis and pneumonia models.
Methodological Strengths
- In vivo validation in murine sepsis and pneumonia models with pharmacologic intervention
- Mechanistic dissection identifying receptor (FPR2) and ISGF3–necrosome signaling axis
Limitations
- Findings are preclinical; human immune context and dosing safety remain untested
- Fludarabine’s immunosuppressive risks may limit sepsis use without careful stratification
Future Directions: Evaluate STAT1-targeted anti-virulence therapy in larger animal models; define safety, pharmacodynamics, and synergy with antibiotics; explore biomarkers (e.g., PSMα3 activity) for patient selection.
The growing antibiotic resistance and high mortality rates associated with methicillin-resistant Staphylococcus aureus (MRSA) pose a global health threat, highlighting the urgent need for novel therapeutic strategies. Phenol-soluble modulin α3 (PSMα3) is a critical virulence factor in MRSA pathogenesis and immune evasion. However, its underlying mechanisms remain unclear. Here, we demonstrate that PSMα3 promotes both M1 macrophage polarization and necroptosis. These processes are mechanistically linked through an interaction between the interferon-stimulated gene factor 3 (ISGF3) and necrosome complexes, with formyl peptide receptor 2 (FPR2) serving as the key receptor. Based on this mechanism, we show that targeting signal transducer and activator of transcription 1 (STAT1), a key component of the ISGF3 complex, with the clinically approved drug fludarabine effectively mitigates MRSA infection in murine sepsis and pneumonia models. These findings reveal the mechanisms of MRSA pathogenesis and highlight the potential of anti-virulence strategies as innovative therapeutic approaches against MRSA infections.
2. Lactylation of histone H3K18 promotes autophagic gene expression to mitigate immunosuppression in sepsis.
The study identifies histone H3K18 lactylation as a metabolic–epigenetic checkpoint that directly activates ATG5/ATG16L1 to sustain autophagy and antibacterial function during sepsis. Lactate supplementation restored H3K18la and autophagic flux, while an H3K18R mutant abolished rescue, establishing causality.
Impact: Defines a novel, actionable mechanism linking glycolysis to autophagy gene control in sepsis immunosuppression, providing concrete molecular targets (H3K18la, ATG5/ATG16L1).
Clinical Implications: Supports exploration of metabolic–epigenetic interventions (e.g., modulating lactylation or downstream autophagy pathways) as adjuncts in sepsis; immediate clinical application requires safety evaluation given risks of lactate manipulation.
Key Findings
- Glycolytic dysfunction reduces H3K18 lactylation, silencing autophagy and impairing bacterial clearance in LPS-tolerant macrophages and CLP mice.
- CUT&Tag-seq identified ATG5 and ATG16L1 as direct transcriptional targets of H3K18la.
- Lactate supplementation restored H3K18la and autophagy; H3K18R mutation abolished rescue, while ATG5/ATG16L1 overexpression rescued autophagy.
Methodological Strengths
- Multi-level mechanistic validation including CUT&Tag-seq, genetic perturbation (H3K18R), and in vivo CLP models
- Convergent functional readouts (autophagic flux, bacterial clearance) across systems
Limitations
- Translational relevance of lactate dosing and potential metabolic adverse effects remain uncertain
- Human validation and clinical biomarkers of H3K18la are not yet established
Future Directions: Develop selective modulators of histone lactylation or ATG5/ATG16L1 transcription; validate H3K18la as a biomarker in patient cohorts; test combinatorial strategies with immunomodulators or antibiotics.
Sepsis-induced immunosuppression is associated with both autophagy impairment and glycolytic dysfunction. However, it is unclear how metabolic dysfunction drives epigenetic reprogramming, thereby reducing autophagy in sepsis. Here, we demonstrate that glycolytic dysfunction and consequent lactate deficiency epigenetically silence autophagy by reducing histone H3 lysine 18 lactylation (H3K18la). Using LPS-tolerant macrophages and CLP-induced immunosuppressive murine models, we observed that reduced lactate levels and global lactylation correlated with impaired autophagic flux and diminished bacterial clearance, with H3K18la emerging as the most consistently downregulated histone lactylation mark. Mechanistically, CUT&Tag-seq revealed ATG5 and ATG16L1 as direct transcriptional targets of H3K18la. Moreover, lactate supplementation restored H3K18la deposition, upregulated ATG5/ATG16L1 expression, and rescued autophagy and bactericidal function. Then a lactylation-deficient H3K18R mutation abolished lactate-mediated rescue, while overexpression of ATG5/ATG16L1 restored autophagy even under H3K18la-deficient conditions. Overall, these findings implicate H3K18la as a metabolic-epigenetic checkpoint linking glycolysis to autophagy gene expression, providing a mechanistic framework for understanding how metabolic dysfunction may contribute to immunosuppression in sepsis.
3. Dynamic gut responses to sepsis uncovered by multi-omics profiling in a rodent model.
Time-resolved multi-omics in a pneumonia-induced sepsis model revealed coordinated shifts in mononuclear phagocytes, T cells, structural and mucus cells, alongside microbiome, metabolite, and proteomic alterations. The shared fluctuation patterns across modalities highlight cross-kingdom interactions that may be leveraged for gut-targeted sepsis interventions.
Impact: Provides a systems-level map of gut ecosystem remodeling during sepsis, integrating cells, microbiome, metabolites, and proteins to nominate candidate therapeutic nodes.
Clinical Implications: Suggests that precision, gut-directed therapies (e.g., barrier support, microbiome or metabolite modulation) should be timed to stage-specific cellular–microbial shifts in sepsis.
Key Findings
- Mononuclear phagocytes and T cells exhibited compositional and transcriptional shifts over sepsis progression.
- Structural and mucus-producing cells adapted roles in antigen presentation and intestinal homeostasis.
- Coordinated alterations in microbiome composition, metabolite levels, and colonic proteins showed shared fluctuation patterns.
Methodological Strengths
- Longitudinal, multi-omics integration across cellular, microbial, metabolic, and proteomic layers
- Disease-relevant pneumonia-induced sepsis model with temporal resolution
Limitations
- Rodent findings may not fully translate to human sepsis heterogeneity
- Descriptive multi-omics without interventional validation limits causal inference
Future Directions: Perturbation experiments to test candidate targets; validate signatures in human cohorts; develop timed, gut-focused interventions based on stage-specific networks.
Sepsis reflects an immune dysregulation in response to infection, and the intestine functions as the largest immune organ in the human body. However, the multidimensional dynamic changes within the gut environment during the progression of sepsis remain incompletely understood. Here, we show the alterations in the gut over the course of pneumonia-induced sepsis through the analysis of cellular, microbial, metabolic, and protein profiles over time. We demonstrate that subsets of immune cells, including mononuclear phagocytes and T cells, undergo compositional and transcriptional shifts. Simultaneously, specific structural cells and mucus-producing cells exhibit adapted roles in antigen presentation and the regulation of intestinal homeostasis. Furthermore, we detail alterations in the gut microbiome composition, metabolite levels, and colonic protein expression, identifying shared fluctuation patterns across these biological dimensions. These findings outline the interactions among the gut microbiome, cellular activity, and immune responses, providing potential therapeutic targets for future sepsis management.